Estrogen

Perimenopausal women using estrogen for at least 10 years before menopause had 60% lower odds of breast cancer, heart attack, and stroke compared to non-users; postmenopause starters had lower breast cancer and heart attack risk but 4.9% higher stroke likelihood.

Review of 74 human studies shows estrogen replacement therapy reduces cardiovascular mortality by 35%, osteoporosis risk by 50%, and menopausal symptoms, with potential benefits for memory, Alzheimer disease, tooth loss, and colon cancer prevention.

Estrogen supplementation in postmenopausal women with low quality of life improved quality of life and reduced plasma lipoperoxides; it also reduces leukocyte invasion and increases satellite cells for skeletal muscle regeneration.

FDA-approved estrogen therapies relieve hot flashes, night sweats, vaginal dryness, and dyspareunia in menopausal women.

Clinical studies and meta-analyses confirm hormone replacement therapy improves vasomotor symptoms, vaginal dryness, lipid profiles, bone density, cognitive retention, skin suppleness, sexual desire, muscle strength, and reduces cardiovascular risk and osteoporosis in perimenopausal and postmenopausal women.

Review of 74 human studies shows estrogen replacement therapy reduces cardiovascular mortality by 35%, osteoporosis risk by 50%, and menopausal symptoms, with potential benefits for memory, Alzheimer disease, tooth loss, and colon cancer prevention.

Perimenopausal women using estrogen for at least 10 years before menopause had 60% lower odds of breast cancer, heart attack, and stroke compared to non-users; postmenopause starters had lower breast cancer and heart attack risk but 4.9% higher stroke likelihood.

FDA-approved estrogen therapies relieve hot flashes, night sweats, vaginal dryness, and dyspareunia in menopausal women.

Clinical studies and meta-analyses confirm hormone replacement therapy improves vasomotor symptoms, vaginal dryness, lipid profiles, bone density, cognitive retention, skin suppleness, sexual desire, muscle strength, and reduces cardiovascular risk and osteoporosis in perimenopausal and postmenopausal women.

Review of 74 human studies shows estrogen replacement therapy reduces cardiovascular mortality by 35%, osteoporosis risk by 50%, and menopausal symptoms, with potential benefits for memory, Alzheimer disease, tooth loss, and colon cancer prevention.

Perimenopausal women using estrogen for at least 10 years before menopause had 60% lower odds of breast cancer, heart attack, and stroke compared to non-users; postmenopause starters had lower breast cancer and heart attack risk but 4.9% higher stroke likelihood.

FDA-approved estrogen therapies relieve hot flashes, night sweats, vaginal dryness, and dyspareunia in menopausal women.

Clinical studies and meta-analyses confirm hormone replacement therapy improves vasomotor symptoms, vaginal dryness, lipid profiles, bone density, cognitive retention, skin suppleness, sexual desire, muscle strength, and reduces cardiovascular risk and osteoporosis in perimenopausal and postmenopausal women.

Perimenopausal women using estrogen for at least 10 years before menopause had 60% lower odds of breast cancer, heart attack, and stroke compared to non-users; postmenopause starters had lower breast cancer and heart attack risk but 4.9% higher stroke likelihood.

FDA-approved estrogen therapies relieve hot flashes, night sweats, vaginal dryness, and dyspareunia in menopausal women.

Clinical studies and meta-analyses confirm hormone replacement therapy improves vasomotor symptoms, vaginal dryness, lipid profiles, bone density, cognitive retention, skin suppleness, sexual desire, muscle strength, and reduces cardiovascular risk and osteoporosis in perimenopausal and postmenopausal women.

Estrogen supplementation in postmenopausal women with low quality of life improved quality of life and reduced plasma lipoperoxides; it also reduces leukocyte invasion and increases satellite cells for skeletal muscle regeneration.

Perimenopausal women using estrogen for at least 10 years before menopause had 60% lower odds of breast cancer, heart attack, and stroke compared to non-users; postmenopause starters had lower breast cancer and heart attack risk but 4.9% higher stroke likelihood.

Perimenopausal women using estrogen for at least 10 years before menopause had 60% lower odds of breast cancer, heart attack, and stroke compared to non-users; postmenopause starters had lower breast cancer and heart attack risk but 4.9% higher stroke likelihood.

Clinical studies and meta-analyses confirm hormone replacement therapy improves vasomotor symptoms, vaginal dryness, lipid profiles, bone density, cognitive retention, skin suppleness, sexual desire, muscle strength, and reduces cardiovascular risk and osteoporosis in perimenopausal and postmenopausal women.

Perimenopausal women using estrogen for at least 10 years before menopause had 60% lower odds of breast cancer, heart attack, and stroke compared to non-users; postmenopause starters had lower breast cancer and heart attack risk but 4.9% higher stroke likelihood.

Clinical studies and meta-analyses confirm hormone replacement therapy improves vasomotor symptoms, vaginal dryness, lipid profiles, bone density, cognitive retention, skin suppleness, sexual desire, muscle strength, and reduces cardiovascular risk and osteoporosis in perimenopausal and postmenopausal women.

Perimenopausal women using estrogen for at least 10 years before menopause had 60% lower odds of breast cancer, heart attack, and stroke compared to non-users; postmenopause starters had lower breast cancer and heart attack risk but 4.9% higher stroke likelihood.

Clinical studies and meta-analyses confirm hormone replacement therapy improves vasomotor symptoms, vaginal dryness, lipid profiles, bone density, cognitive retention, skin suppleness, sexual desire, muscle strength, and reduces cardiovascular risk and osteoporosis in perimenopausal and postmenopausal women.

Perimenopausal women using estrogen for at least 10 years before menopause had 60% lower odds of breast cancer, heart attack, and stroke compared to non-users; postmenopause starters had lower breast cancer and heart attack risk but 4.9% higher stroke likelihood.

Clinical studies and meta-analyses confirm hormone replacement therapy improves vasomotor symptoms, vaginal dryness, lipid profiles, bone density, cognitive retention, skin suppleness, sexual desire, muscle strength, and reduces cardiovascular risk and osteoporosis in perimenopausal and postmenopausal women.

FDA-approved estrogen therapies relieve hot flashes, night sweats, vaginal dryness, and dyspareunia in menopausal women.

Clinical studies and meta-analyses confirm hormone replacement therapy improves vasomotor symptoms, vaginal dryness, lipid profiles, bone density, cognitive retention, skin suppleness, sexual desire, muscle strength, and reduces cardiovascular risk and osteoporosis in perimenopausal and postmenopausal women.

Perimenopausal women using estrogen for at least 10 years before menopause had 60% lower odds of breast cancer, heart attack, and stroke compared to non-users; postmenopause starters had lower breast cancer and heart attack risk but 4.9% higher stroke likelihood.

Estrogen therapy lowers risk of osteoporosis, heart disease, dementia, and mood changes caused by low estrogen in menopausal women.